Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
•
Male Breast Cancer
How would you manage endocrine therapy in a male patient with gBRCA2 with a metachronous contralateral ER+ breast CA that occurred while on adjuvant tamoxifen for a different ER+ breast CA?
Related Questions
In which patients do you offer adjuvant bisphosphates in breast cancer treatment?
Is there evidence for development of more severe autoimmune toxicities for young patients vs older patients on immune checkpoint inhibitors?
For which patients, if any, do you typically order additional imaging workup for staging in early-stage breast cancer?
What adjuvant treatment approach would you choose for a premenopausal woman with lymph node positive poorly differentiated metaplastic breast cancer that is ER low+, PR+, HER2 negative?
Will you consider PD-L1 expression to estimate the likelihood of response to neoadjuvant chemotherapy in ER positive/HER-2 negative breast cancer after results of the Keynote-756?
How do you decide between neoadjuvant chemotherapy vs neoadjuvant endocrine treatment in postmenopausal women with node involvement?
Can you safely proceed with breast irradiation during treatment with immunotherapy?
How do you treat a patient with TNBC, BRCA WT, who received KEYNOTE 522 with residual disease post neoadjuvant therapy?
How would you approach adjuvant systemic therapy in a HR+ premenopausal patient over the age of 50?
Is any hormonal monitoring necessary for males with breast cancer on adjuvant aromatase inhibitor and LHRH agonist (Lupron)?
